BackProtagonist Therapeutics Overview
Protagonist Therapeutics Inc

Protagonist Therapeutics Target Price

Analysts' average 12-month price target for Protagonist Therapeutics is $160.

Get informed when a big investor buys or sells

+ Follow

Share Price

$145.72

Average Target Price

$164.2512.7% upside

12 analysts in the last 4 months

High: $190 | Low: $110

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-01BMO CapitalEvan Seigerman$19030.4% upsideOpen
2026-09-01BarclaysEtzer Darout$18023.5% upsideOpen
2026-08-31H.C. Wainwright$17016.7% upsideOpen
2026-08-17BMO Capital$17822.2% upsideOpen
2026-08-10Truist FinancialSrikripa Devarakonda$17016.7% upsideOpen
2026-08-10Wedbush$17318.7% upsideOpen
2026-08-10Goldman SachsRichard Law$18627.6% upsideOpen
2026-08-06Barclays$1535% upsideOpen
2026-07-17Johnson Rice$16513.2% upsideOpen
2026-07-14Barclays$1513.6% upsideOpen
2026-07-07Truist Financial$1450.5% downsideOpen
2026-05-06Goldman Sachs$11024.5% downsideOpen
2026-04-14Truist FinancialSrikripa Devarakonda$12117% downsideOpen
2026-03-18JefferiesRoger Song$12117% downsideOpen
2026-01-30H.C. Wainwright$11719.7% downsideOpen
2026-01-05Truist Financial$11024.5% downsideOpen
2025-12-17Barclays$10825.9% downsideOpen
2025-10-28Truist FinancialSrikripa Devarakonda$8839.6% downsideOpen
2025-10-13Johnson Rice$11223.1% downsideOpen
2025-10-07Johnson Rice$7449.2% downsideOpen
2025-09-16Barclays$7250.6% downsideOpen
2025-03-11Wedbush$7052% downsideOpen
2025-03-11Truist Financial$7647.8% downsideOpen
2025-03-03BTIG$7349.9% downsideOpen
2024-12-05BMO CapitalEtzer Darout$6257.5% downsideOpen
2024-11-22Truist FinancialSrikripa Devarakonda$6058.8% downsideOpen
2024-09-12H.C. WainwrightDouglas Tsao$5065.7% downsideOpen
2024-06-17H.C. WainwrightDouglas Tsao$3873.9% downsideOpen

Protagonist Therapeutics (PTGX) FAQ

Protagonist Therapeutics (PTGX) currently reports a target price of $160. Use the charts on this page to explore Protagonist Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Protagonist Therapeutics is $160, about 12.7% upside from the current share price of $145.72. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $160, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Protagonist Therapeutics, and consider following PTGX for alerts when major investors trade the stock.

Protagonist Therapeutics is classified in the Healthcare sector. On target price, it currently shows $160. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PTGX with unrelated industries.